Celerion Acquires Early Stage Clinical Research Operations from MDS Pharma Services
Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada.
Life sciences and CRO industry veteran Susan Thornton, Ph.D., is Chief Executive Officer of Celerion. “I'm energized by the prospect of taking this great business to the next level of market leadership,” she said. “We look forward to continuing to provide our pharmaceutical, biotechnology and generic clients with early stage clinical research services. Like the company I am leading, my roots are in MDS Pharma Services.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
